{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:46:49Z","timestamp":1761630409387,"version":"build-2065373602"},"reference-count":21,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,5,1]],"date-time":"2006-05-01T00:00:00Z","timestamp":1146441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2006,5]]},"DOI":"10.1016\/j.jaad.2005.08.025","type":"journal-article","created":{"date-parts":[[2006,4,24]],"date-time":"2006-04-24T22:58:04Z","timestamp":1145919484000},"page":"892-895","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":30,"title":["Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab"],"prefix":"10.1016","volume":"54","author":[{"given":"Timothy H.","family":"Clayton","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Ogden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark D.J.","family":"Goodfield","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2005.08.025_bib1","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/archderm.1979.04010120007006","article-title":"Subacute cutaneous lupus erythematosus: a cutaneous marker for a distinct lupus erythematosus subset","volume":"115","author":"Sontheimer","year":"1979","journal-title":"Arch Dermatol"},{"issue":"Suppl 1","key":"10.1016\/j.jaad.2005.08.025_bib2","first-page":"71S","article-title":"Subacute cutaneous lupus erythematosus","volume":"105","author":"David-Bajar","year":"1995","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2005.08.025_bib3","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.4049\/jimmunol.157.11.4986","article-title":"Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1","volume":"157","author":"Werther","year":"1996","journal-title":"J Immunol"},{"issue":"5 Pt 1","key":"10.1016\/j.jaad.2005.08.025_bib4","first-page":"830","article-title":"Guidelines of care for cutaneous lupus erythematosus","volume":"34","author":"Drake","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.08.025_bib5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1159\/000246899","article-title":"The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus","volume":"189","author":"Feldmann","year":"1994","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2005.08.025_bib6","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1067\/mjd.2002.114608","article-title":"Methotrexate treatment for refractory subacute cutaneous lupus erythematosus","volume":"46","author":"Kuhn","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.08.025_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1046\/j.1365-2133.2002.04875.x","article-title":"Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil","volume":"147","author":"Schanz","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2005.08.025_bib8","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1001\/archderm.1986.01660140060018","article-title":"Mechanism-oriented assessment of isotretinoin in chronic or subacute cutaneous lupus erythematosus","volume":"122","author":"Newton","year":"1986","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2005.08.025_bib9","first-page":"1429","article-title":"Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy","volume":"27","author":"Ordi-Ros","year":"2000","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2005.08.025_bib10","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/j.1365-2133.1986.tb05720.x","article-title":"Treatment of chronic discoid lupus erythematosus with an oral gold compound (Auranofin)","volume":"115","author":"Dalziel","year":"1986","journal-title":"Br J Dermatol"},{"issue":"2 Pt 1","key":"10.1016\/j.jaad.2005.08.025_bib11","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0190-9622(95)90134-5","article-title":"Clofazimine: a review of its medical uses and mechanisms of action","volume":"32","author":"Arbiser","year":"1995","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2005.08.025_bib12","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/rheumatology\/40.8.876","article-title":"Serum interleukin-15 is elevated in systemic lupus erythematosus","volume":"40","author":"Aringer","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2005.08.025_bib13","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1191\/0961203302lu160oa","article-title":"Increased bioactive TNF in human systemic lupus erythematosus: associations with cell death","volume":"11","author":"Aringer","year":"2002","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2005.08.025_bib14","first-page":"303","article-title":"Circulating levels of tumor necrosis factor soluble receptors in systemic lupus erythematosus are significantly higher than in other rheumatic diseases and correlate with disease activity","volume":"24","author":"Abay","year":"1997","journal-title":"J Rheumatol"},{"key":"10.1016\/j.jaad.2005.08.025_bib15","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1177\/096120339300200605","article-title":"Profiles of cytokines (TNF and IL6) and acute phase proteins (CRP and 1AG) related to disease course in patients with systemic lupus erythematosus","volume":"2","author":"Meijer","year":"1993","journal-title":"Lupus"},{"key":"10.1016\/j.jaad.2005.08.025_bib16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1002\/anr.1780320206","article-title":"Tumor necrosis factor in the serum of patients with systemic lupus erythematosus","volume":"32","author":"Maury","year":"1989","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2005.08.025_bib17","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1136\/ard.2003.019323","article-title":"Lupus erythematosus with leflunomide: induction or reactivation?","volume":"64","author":"Gensburger","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jaad.2005.08.025_bib18","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1002\/art.20576","article-title":"Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study","volume":"50","author":"Aringer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2005.08.025_bib19","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1093\/rheumatology\/40.11.1317","article-title":"Etanercept-induced subacute cutaneous lupus erythematosus","volume":"40","author":"Bleumink","year":"2001","journal-title":"Rheumatology"},{"key":"10.1016\/j.jaad.2005.08.025_bib20","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1002\/art.10271","article-title":"Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent","volume":"46","author":"Fautrel","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2005.08.025_bib21","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1396-0296.2004.04042.x","article-title":"Efalizumab in the treatment of psoriasis","volume":"17","author":"Leonardi","year":"2004","journal-title":"Dermatol Ther"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205026691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962205026691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:02:35Z","timestamp":1759269755000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962205026691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,5]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["S0190962205026691"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2005.08.025","relation":{},"ISSN":["0190-9622"],"issn-type":[{"type":"print","value":"0190-9622"}],"subject":[],"published":{"date-parts":[[2006,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of refractory subacute cutaneous lupus erythematosus with efalizumab","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2005.08.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2006 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}